Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 4, 2015, Pages 523-525

  Siddiqui, Salman H ^a   Guasconi, Alessandro ^b   Vestbo, Jørgen ^c   Jones, Paul ^d   Agusti, Alvar ^e,f   Paggiaro, Pierluigi ^g   Wedzicha, Jadwiga A ^h   Singh, Dave ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g UNIVERSITY OF PISA   (Italy)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BIOLOGICAL MARKER; FORMOTEROL FUMARATE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; GLUCOCORTICOID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; EOSINOPHIL; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; MAJOR CLINICAL STUDY; METERED DOSE INHALER; PRIORITY JOURNAL; TREATMENT RESPONSE; BLOOD; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; LEUKOCYTE COUNT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BECLOMETHASONE; BIOMARKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHILS; ETHANOLAMINES; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE COUNT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84939433292     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201502-0235LE     Document Type: Letter

References (7)

1. Agusti A. The path to personalised medicine in COPD. Thorax 2014;69:857-864.
2. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R; ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-1700.
3. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-671.
4. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.
5. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55.
6. Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, et al.; FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med 2014;108:1153-1162.
7. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-659.